Avrupa Birliği - Almanca - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateronacetat - prostata-neoplasmen - endokrine therapie - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

bayer ag - darolutamide - prostatahyperplasie neubildungen, kastration-resistentem - endokrine therapie - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

accord healthcare s.l.u. - cabazitaxel - prostatahyperplasie neubildungen, kastration-resistentem - antineoplastische mittel - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatahyperplasie neubildungen, kastration-resistentem - antineoplastische mittel - treatment of adult patients with prostate cancer.

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

bioforce gmbh - solidago virgaurea (pot.-angaben), serenoa repens (pot.-angaben), echinacea purpurea (pot.-angaben) - flüssigkeit - solidago virgaurea (pot.-angaben) 3.g; serenoa repens (pot.-angaben) 95.g; echinacea purpurea (pot.-angaben) 2.g

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - prostata-neoplasmen - diagnostische radiopharmaka - dieses arzneimittel ist nur für diagnostische zwecke bestimmt. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

vitorgan arzneimittel gmbh - prostata bovis (pot.-angaben) - tablette - prostata bovis (pot.-angaben) 250.mg

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

vitorgan arzneimittel gmbh - prostata bovis (pot.-angaben) - flüssige verdünnung zur injektion - prostata bovis (pot.-angaben) 20.mg

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

strathmann gmbh & co. kg - brennnesselwurzel, te mit methanol/methanol-wasser (%-angaben) - kapsel - brennnesselwurzel, te mit methanol/methanol-wasser (%-angaben) 150.mg

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

medice arzneimittel pütter gmbh & co. kg - chimaphila umbellata (pot.-angaben) - flüssige verdünnung - chimaphila umbellata (pot.-angaben) 10.ml